23/12/2024 - Institutional news
The Digestive Tumor Treatment Group (TTD) has awarded one of its grants for research projects on digestive tumors to Dr. Jenniffer Linares, a researcher from the Colorectal Cancer Precision Medicine Research Group, led by Dr. Clara Montagut at the Hospital del Mar Research Institute. The award ceremony took place during the 32nd TTD International Symposium on Advances in Digestive Tumor Treatments. The grant is for the project titled "Clinical impact of CAF-secreted biomarkers in RAS wild-type metastatic CRC patients treated within the CR-SEQUENCE clinical trial." Its goal is to identify the predictive value of biomarkers derived from the tumor microenvironment to anticipate the response to chemotherapy and anti-EGFR treatments in patients with RAS wild-type metastatic colorectal cancer.
Més informació "Grant from the Digestive Tumor Treatment Group for Dr. Jenniffer Linares"
12/12/2024 - General information
The SAGITTARIUS clinical trial has officially begun with the inclusion of the first six patients in the project. Among them, the first at the Hospital del Mar, a collaborating center in the study, which is coordinated in Spain by Dr. Clara Montagut, head of the Gastrointestinal Tumors section of the Medical Oncology Service and coordinator of the Colorectal Cancer Precision Medicine Research Group at the Hospital del Mar Research Institute.
Més informació "The SAGITTARIUS clinical trial, led by the Hospital del Mar in Spain, gets underway"
18/11/2024 - Press release
The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by VHIO investigators, CAR T cells targeting p95HER2 have been engineered to secrete the TECH2Me bispecific antibody. Both therapies specifically and independently recognize tumor cells. In addition, the TECH2Me bispecific antibody activates immune cells within the tumor microenvironment. This dual mechanism of action has demonstrated safety and achieved complete and durable antitumor responses in patient-derived models of HER2+ p95HER2-expressing solid tumors. Published in Nature Communications, results of this VHIO-led study have provided the rationale for the application of a phase 1 first-in-human clinical trial, currently in the approval process, to assess this novel therapeutic strategy in patients with HER2-driven solid tumors.
13/11/2024 - General information
The "la Caixa" Foundation has selected 29 new high-impact, socially relevant biomedical research projects. One of these projects, led by the Center for Genomic Regulation, includes participation by Dr. Toni Celià-Terrassa, coordinator of the Cancer Stem Cells and Metastasis Dynamics Research Group at the Hospital del Mar Research Institute.
06/11/2024 - Press release
This study will be conducted in collaboration with the Josep Carreras Leukemia Research Institute, and researchers from Finland, the Netherlands, and the United Kingdom will participate. The goal is to develop and validate protocols and systems for generating laboratory-derived stem cells to regenerate patients' blood. The European Research Council, which provides these grants, is the leading funding organization for advanced and excellent research on the continent. It is an organization created by the European Union.
05/06/2024 - Press release
A scientific team led by Dr Anna Bigas, from the Hospital del Mar Research Institute and the Josep Carreras Institute, has described the role of the IκBα protein in the differentiation process of haematopoietic cells. In the absence of this protein, the stem cells enter quiescence, acquire a dormant state and maintain their potential, which may allow them to be transplanted for therapeutic uses in leukaemia or blood diseases of genetic origin. This is an important step towards being able to generate these types of cells in the lab, preventing them from differentiating and turning into other cells too early.
03/05/2024 - Press release
Natural Killer (NK) cells, when exposed to antibody treatment used against HER2-positive breast cancer, secrete specific types of cytokines that activate the immune response against tumor cells. Researchers have confirmed that patients with NK lymphocytes present in the tumor environment show a better response to treatment, thanks to this mechanism. This confirms the feasibility of using cytokines secreted by NK cells as markers of response to anti-HER2 antibodies with a simple blood test. It also reaffirms various clinical trials using these lymphocytes to bolster treatment in patients with metastatic HER2-positive breast cancer.
15/04/2024 - General information
The Reial Acadèmia de Medicina de Catalunya chose, in a plenary session held on April 9, Dr. Manuel Pera as the new full academician of the institution. Dr. Pera, who was already a corresponding academic since 2022, will be attached to the surgery section of the institution. The section chief of the Gastrointestinal Surgery Unit of the Hospital del Mar and researcher at the center's Research Institute, thus becomes one of the sixty full academicians of the institution. The election is made by a vote among the members themselves. The ceremony of entry into the Royal Academy will take place in the coming months.
16/11/2023 - Institutional news
The Universidad Francisco de Victoria (UFV), in association with the science and technology company MERCK, presents awards to researchers who have made significant clinical and scientific contributions in the field of cancer immunology research.
A study involving the Hospital del Mar Research Institute, the Vall d'Hebron Institut d'Oncologia, IDIBELL, and the Institut Català d'Oncologia suggests that combining chemotherapy with drugs that can inhibit two cell signaling pathways involved in tumor progression may aid in treatment. The research has analyzed the interaction of the protein IKKα with these pathways, known for their ability to promote the proliferation of tumor cells. This combination has the advantage of reducing treatment toxicity. The study opens the door to new approaches for tumors with the presence of this protein. It is published in the EMBO Journal.
Més informació "A possible new combination of treatments to combat cancer"
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
